Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

NCT03445533 is registered in ClinicalTrials.gov with Idera Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03445533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03445533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Lead sponsor
Idera Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
May 30, 2018
Completion date
June 1, 2021
Enrollment
481 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma